THYROID HORMONES (THS) ACTING THROUGH INTEGRIN ΑVΒ3 INDUCE ONCOGENIC SIGNALING PATHWAYS INVOLVED IN T CELL LYMPHOMA (TCL) PROGRESSION

DEBERNARDI MM; DÍAZ ALBUJA JA; STERLE HA; PAULAZO, MARÍA ALEJANDRA; DÍAZ FLAQUÉ MC; CAMPOS HAEDO MN; GONZALEZ G; ROSEMBLIT C.; CREMASCHI GA; CAYROL F

Mar del Plata

Congreso; REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022; 2022

SAIC, SAI, SAFIS

Decoding the molecular mechanisms leading to TCL progression is a complex issue due to the diversity of these malignancies. In most TCL patients the JAK/STAT and NF-κB pathways are over-activated. To find new therapeutic targets, these oncogenic pathways, and the activating factors should be studied deeply. Our previous results show that THs, acting via integrin αVβ3, promotes cell proliferation and survival, and induces an angiogenic program in TCL cells. Here we study if THs are one of the factors involved in the activation of these oncogenic pathways. First, we analyzed TCL cell lines corresponding to immature (CUTLL1) and mature (OCI-Ly12, OCI-Ly13.2) human subtypes after 10, 15, and 30 minutes THs treatment. We found that physiological levels of THs significantly increase STAT1, 3, 5, NF-κB, and ERK phosphorylation in all TCL cells (p